| This week's sponsor is SynteractHCR. | | | |
Featured Story | | | Monday, August 28, 2017 Kite Pharma and its hotly anticipated CAR-T medication nabbed a $11.9 billion buyout offer from Gilead Sciences, which has been shopping for oncology assets to diversify away from its flagging hepatitis C franchise. The deal beefs up Gilead's pipeline and puts it toe-to-toe with Novartis for the nascent CAR-T cancer therapy market. |
|
|
Top Stories Monday, August 28, 2017 CSL Behring has paid out $91 million upfront for biotech Calimmune and gains a preclinical asset for sickle cell disease and β-thalassemia, adding to its blood disease pipeline. Monday, August 28, 2017 The spectacular rehabilitation of Aveo's cancer drug tivozanib continues with EU approval as a treatment for advanced kidney cancer. Monday, August 28, 2017 Novartis has bought the rights to Xoma’s gevokizumab. The Swiss Big Pharma is paying $31 million (€26 million) upfront for the anti-IL-1 beta allosteric monoclonal antibody, a price that reflects the battering its prospects took as a late-phase clinical development program unraveled. Monday, August 28, 2017 Philips has signed up to promote HeartFlow’s noninvasive chest pain test alongside its catheters. The deal provides more evidence big healthcare technology players are impressed by HeartFlow FFRct Analysis, which was the subject of agreements with GE Healthcare and Siemens Healthineers earlier this year. Monday, August 28, 2017 Gilead Sciences CEO John Milligan, under pressure from investors for more than a year, has finally pulled the trigger on a deal aimed at growing sales in a new field. The company agreed to plunk down nearly $12 billion for Kite Pharma and its CAR-T candidate, winning Milligan the would-be cancer blockbuster he wanted. Monday, August 28, 2017 The life sciences field presents its own barriers to women's advancement, but in spite of these challenges, women can and do attain top-level positions, start their own companies and otherwise make their marks on the industry. Know a woman in biotech, pharma or medtech who is doing just that? Nominate her for this year's Fiercest Women in Life Sciences feature. Monday, August 28, 2017 2016 was the year of the makeover. The top 10 medtech players are all in varying stages of transformation. Some companies, like Philips and Siemens, are well into their metamorphoses, while others, such as Boston Scientific and Johnson & Johnson, made moves to overhaul their medtech businesses. Resources Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. 2nd Strategic Partnerships for Drug Repurposing Oct 26-27 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London Hear from 130+ Experts Leading the Way in Life Science Marketing October 3-6, 2017 | Philadelphia, PA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA |
